|Videos|July 27, 2017
Dr. Bauml on CAR T-Cell Therapy in Head and Neck Cancer
Author(s)Joshua Bauml, MD
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses CAR T-cell therapy in head and neck cancer.
Advertisement
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses chimeric antigen receptor (CAR) T-cell therapy in head and neck cancer.
There could be a place for CAR T-cell therapy in head and neck cancer, says Bauml, but there are limitations.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – January 14, 2026
2
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL
3
Steven W. Pipe, MD, on Integrating Gene Therapy into Clinical Care for Hemophilia B
4
Data Roundup: December 2025 Features Updates from ASH and CTAD
5